These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 23147743)

  • 41. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli.
    Santos KVD; Nicoli JR; Martins WA; Coutinho SC; Apolônio ACM; Diniz CG; Carvalho MAR; Farias LM
    J Med Microbiol; 2007 Nov; 56(Pt 11):1576-1579. PubMed ID: 17965366
    [No Abstract]   [Full Text] [Related]  

  • 43. Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing
    Cojutti PG; Pai MP; Tonetti T; Siniscalchi A; Viale P; Pea F
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0140423. PubMed ID: 38411995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
    Marie JP; Marjanovic Z; Vekhoff A; Bouvet A; Chast F; Levy V; Baudard M; Legrand O; Rio B; Delmer A; Zittoun R
    Support Care Cancer; 1999 Mar; 7(2):89-94. PubMed ID: 10089089
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin.
    Delattre IK; Musuamba FT; Verbeeck RK; Dugernier T; Spapen H; Laterre PF; Wittebole X; Cumps J; Taccone FS; Vincent JL; Jacobs F; Wallemacq PE
    Clin Biochem; 2010 Apr; 43(6):589-98. PubMed ID: 20036226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pulmonary penetration of piperacillin and tazobactam in critically ill patients.
    Felton TW; McCalman K; Malagon I; Isalska B; Whalley S; Goodwin J; Bentley AM; Hope WW
    Clin Pharmacol Ther; 2014 Oct; 96(4):438-48. PubMed ID: 24926779
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in the use of broad-spectrum antibiotics after cefepime shortage: a time series analysis.
    Plüss-Suard C; Pannatier A; Ruffieux C; Kronenberg A; Mühlemann K; Zanetti G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):989-94. PubMed ID: 22123703
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.
    Felton TW; Roberts JA; Lodise TP; Van Guilder M; Boselli E; Neely MN; Hope WW
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4094-102. PubMed ID: 24798288
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative in vitro activity of cefepime against strains isolated from intensive care and haematology patients.
    Vanpoucke H; Claeys G; De Grauwe E; Verschraegen G
    Acta Clin Belg; 2000; 55(1):16-21. PubMed ID: 10783503
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Variability of piperacillin concentrations in relation to tazobactam concentrations in critically ill patients.
    Zander J; Döbbeler G; Nagel D; Scharf C; Huseyn-Zada M; Jung J; Frey L; Vogeser M; Zoller M
    Int J Antimicrob Agents; 2016 Oct; 48(4):435-9. PubMed ID: 27476810
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose optimization of piperacillin/tazobactam in critically ill children.
    De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
    J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
    Mullins BP; Kramer CJ; Bartel BJ; Catlin JS; Gilder RE
    Ann Pharmacother; 2018 Jul; 52(7):639-644. PubMed ID: 29442542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Jang SM; Gharibian KN; Lewis SJ; Fissell WH; Tolwani AJ; Mueller BA
    J Clin Pharmacol; 2018 Oct; 58(10):1254-1265. PubMed ID: 29746711
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Seo YB; Lee J; Kim YK; Lee SS; Lee JA; Kim HY; Uh Y; Kim HS; Song W
    BMC Infect Dis; 2017 Jun; 17(1):404. PubMed ID: 28592240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem.
    Raveh D; Muallem-Zilcha E; Greenberg A; Wiener-Well Y; Schlesinger Y; Yinnon AM
    QJM; 2006 Jun; 99(6):397-406. PubMed ID: 16682440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. β-lactam dosing at the early phase of sepsis: Performance of a pragmatic protocol for target concentration achievement in a prospective cohort study.
    Winiszewski H; Despres C; Puyraveau M; Lagoutte-Renosi J; Montange D; Besch G; Floury SP; Chaignat C; Labro G; Vettoretti L; Clairet AL; Capellier G; Vivet B; Piton G
    J Crit Care; 2022 Feb; 67():141-146. PubMed ID: 34768176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.